Phase I/II Vaccine Study Targeting Novel HLA-A2-Restricted CTL Epitopes in Combination With Poly-ICLC in Patients With Recurrent Malignant Glioma
Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma. ASCO 2011. Abstract
